Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Abstract Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients each year in the United States. DIPG is noted for its lethality, as fewer than 1% of patients survive to five years. Multiple clinical trials involving chemotherapy, radiotherapy,...

Full description

Bibliographic Details
Main Authors: Xiaolei Lian, Dina Kats, Samuel Rasmussen, Leah R. Martin, Anju Karki, Charles Keller, Noah E. Berlow
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Acta Neuropathologica Communications
Subjects:
Diffuse intrinsic pontine glioma
Antibody–drug conjugates
Immunotherapy
IL13Rα2
Pediatric cancer
Online Access:https://doi.org/10.1186/s40478-021-01184-9

Internet

https://doi.org/10.1186/s40478-021-01184-9

Similar Items